METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Clinical trials for METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to shrink dangerous liver fat and shed pounds
Disease control Not yet recruitingThis study is testing if a new investigational pill, CS060380, works better than a placebo when added to an approved weight-loss injection (semaglutide) for people who have both a serious fatty liver disease (MASH) and obesity. About 120 adults in China will take either the new p…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Scientists probe Gut's role in silent liver epidemic
Knowledge-focused Not yet recruitingThis study aims to understand how gut bacteria might contribute to fatty liver disease (MASLD) by producing specific substances. Researchers will analyze stool and blood samples from 24 participants—some with MASLD and some healthy—to measure these bacterial products and identify…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC
-
First human tests begin for new liver disease drug
Knowledge-focused Not yet recruitingThis is the first human study of a new drug called QL2401, which is being developed for a serious liver condition called MASH. The study will test the safety and how the drug moves through the body in 70 healthy Chinese adults. Participants will receive either the drug or a place…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:19 UTC